Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Taltirelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR known ✓ | P34981 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taltirelin SCHEMBL13993039 | 1.00 | TRHR (0.73) | TRHR | |
| Taltirelin SCHEMBL30892167 | 0.99 | TRHR (0.72) | TRHR | |
| Taltirelin SCHEMBL2289290 | 0.99 | TRHR (0.72) | TRHR | |
| Taltirelin SCHEMBL2320945 | 0.96 | TRHR (0.69) | TRHR | |
| Azetirelin SCHEMBL195158 | 0.91 | TRHR (0.85) | TRHR | |
| Taltirelin SCHEMBL2321397 | 0.90 | TRHR (0.61) | TRHR | |
| Taltirelin SCHEMBL22077031 | 0.86 | TRHR (0.65) | TRHR | |
| Taltirelin SCHEMBL21219549 | 0.85 | TRHR (0.57) | TRHR | |
| Taltirelin SCHEMBL21219551 | 0.85 | TRHR (0.57) | TRHR | |
| Taltirelin SCHEMBL14280928 | 0.85 | TRHR (0.57) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4667006-A2 | TALTIRELIN USE | Eolas Research Limited (GB) | 2025-12-24 | — | — | EP | claimed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2025128821-A1 | COMPOSITIONS AND METHODS FOR ADP-RIBOSYLATION FACTOR MOLECULAR TRAFFICKING | JUVENA THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| CN-117899200-A | Medicament for enhancing curative effect of immunotherapy and application of medicament in treating tumors | 华中科技大学 | 2024-04-19 | — | — | CN | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| US-20240122847-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2200610-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | Acadia Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20100035805-A1 | NON-AQUEOUS LIQUID FORMULATION FOR NASAL OR BUCCAL ADMINISTRATION | OPTINOSE AS (NO) | 2010-02-11 | — | — | US | claimed |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | claimed |
| WO-2009039460-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007141541-A1 | INTRANASAL ADMINISTRATION | OPTINOSE AS (NO) | 2007-12-13 | — | — | WO | claimed |
| WO-2007125318-A1 | NON-AQUEOUS LIQUID FORMULATION FOR NASAL OR BUCCAL ADMINISTRATION | OPTINOSE AS (NO) | 2007-11-08 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | TRHR 64/4885 |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | TRHR 400/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | TRHR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.